Drug repurposing to find inhibitors of SARS-CoV-2 main protease
- Autores
- Conti, German Andres; Gómez Chávez, José Leonardo; Angelina, Emilio Luis; Peruchena, Nelida Maria
- Año de publicación
- 2021
- Idioma
- inglés
- Tipo de recurso
- documento de conferencia
- Estado
- versión publicada
- Descripción
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the strain of coronavirus that causes coronavirus disease 2019 (COVID-19), the respiratory illness responsible for the COVID-19 pandemic. As of October 2021, with about 6 billion doses of COVID-19 vaccines administered globally, the world is slowly returning back to normality. However, there is still a need for novel therapeutics for people that contracted the disease either because they were not vaccinated or because the vaccine was not effective for them. Drug repurposing is a strategy for identifying new uses for approved drugs that has the advantage, over conventional approaches that attempt to develop a drug from scratch, that the time frame of the overall process can be significantly reduced because of the few number of clinical trials required. In this work, a structure-based virtual screening of FDA-approved drugs was performed for repositioning as potential inhibitors of the main protease Mpro of SARS-CoV-2. 12 drugs were prioritized from the Virtual Screening campaigns as potential inhibitors of the Mpro enzyme. Some of the selected compounds turned out to be antiviral drugs already being tested in COVID-19 clinical trials or used to alleviate symptoms of the disease. Curiously, the most promising candidate is the naturally occurring broad spectrum antibiotic Oxytetracycline (OTC). This drug has largely outperformed the remaining selected candidates along all filtering steps of the virtual screening workflow. The closely related tetracycline-derived drug Doxycycline (DOX) recently has proven to reduce the viral load in Vero cells infected with SARS-CoV-2. Since OTC but not DOX surpassed the more stringent filters in the late stages of our virtual screening pipeline, we suspect that OTC will show even higher antiviral activity than DOX in viral replication experiments.Considering our computational findings together with the proven antiviral properties of DOX, we believe it is worth testing OTC in prospective viral replication studies. We encourage the scientific community working on COVID-19 projects to include this repurposing candidate on their experimental screening pipelines.
Fil: Conti, German Andres. Universidad Nacional del Nordeste. Facultad de Ciencias Exactas y Naturales y Agrimensura. Departamento de Química. Laboratorio de Estructura Molecular y Propiedades; Argentina
Fil: Gómez Chávez, José Leonardo. Universidad Nacional del Nordeste. Facultad de Ciencias Exactas y Naturales y Agrimensura. Departamento de Química. Laboratorio de Estructura Molecular y Propiedades; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Nordeste. Instituto de Química Básica y Aplicada del Nordeste Argentino. Universidad Nacional del Nordeste. Facultad de Ciencias Exactas Naturales y Agrimensura. Instituto de Química Básica y Aplicada del Nordeste Argentino; Argentina
Fil: Angelina, Emilio Luis. Universidad Nacional del Nordeste. Facultad de Ciencias Exactas y Naturales y Agrimensura. Departamento de Química. Laboratorio de Estructura Molecular y Propiedades; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Nordeste. Instituto de Química Básica y Aplicada del Nordeste Argentino. Universidad Nacional del Nordeste. Facultad de Ciencias Exactas Naturales y Agrimensura. Instituto de Química Básica y Aplicada del Nordeste Argentino; Argentina
Fil: Peruchena, Nelida Maria. Universidad Nacional del Nordeste. Facultad de Ciencias Exactas y Naturales y Agrimensura. Departamento de Química. Laboratorio de Estructura Molecular y Propiedades; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Nordeste. Instituto de Química Básica y Aplicada del Nordeste Argentino. Universidad Nacional del Nordeste. Facultad de Ciencias Exactas Naturales y Agrimensura. Instituto de Química Básica y Aplicada del Nordeste Argentino; Argentina
XI Congreso Argentino de Bioinformática y Biología Computacional
Buenos Aires
Argentina
Asociacion Argentina de Bioinformática y Biología Computacional - Materia
-
Cribado Virtual
COVID-19 - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/170855
Ver los metadatos del registro completo
id |
CONICETDig_2f887ac61d47e182f3f003629241b8a7 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/170855 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Drug repurposing to find inhibitors of SARS-CoV-2 main proteaseConti, German AndresGómez Chávez, José LeonardoAngelina, Emilio LuisPeruchena, Nelida MariaCribado VirtualCOVID-19https://purl.org/becyt/ford/1.2https://purl.org/becyt/ford/1Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the strain of coronavirus that causes coronavirus disease 2019 (COVID-19), the respiratory illness responsible for the COVID-19 pandemic. As of October 2021, with about 6 billion doses of COVID-19 vaccines administered globally, the world is slowly returning back to normality. However, there is still a need for novel therapeutics for people that contracted the disease either because they were not vaccinated or because the vaccine was not effective for them. Drug repurposing is a strategy for identifying new uses for approved drugs that has the advantage, over conventional approaches that attempt to develop a drug from scratch, that the time frame of the overall process can be significantly reduced because of the few number of clinical trials required. In this work, a structure-based virtual screening of FDA-approved drugs was performed for repositioning as potential inhibitors of the main protease Mpro of SARS-CoV-2. 12 drugs were prioritized from the Virtual Screening campaigns as potential inhibitors of the Mpro enzyme. Some of the selected compounds turned out to be antiviral drugs already being tested in COVID-19 clinical trials or used to alleviate symptoms of the disease. Curiously, the most promising candidate is the naturally occurring broad spectrum antibiotic Oxytetracycline (OTC). This drug has largely outperformed the remaining selected candidates along all filtering steps of the virtual screening workflow. The closely related tetracycline-derived drug Doxycycline (DOX) recently has proven to reduce the viral load in Vero cells infected with SARS-CoV-2. Since OTC but not DOX surpassed the more stringent filters in the late stages of our virtual screening pipeline, we suspect that OTC will show even higher antiviral activity than DOX in viral replication experiments.Considering our computational findings together with the proven antiviral properties of DOX, we believe it is worth testing OTC in prospective viral replication studies. We encourage the scientific community working on COVID-19 projects to include this repurposing candidate on their experimental screening pipelines.Fil: Conti, German Andres. Universidad Nacional del Nordeste. Facultad de Ciencias Exactas y Naturales y Agrimensura. Departamento de Química. Laboratorio de Estructura Molecular y Propiedades; ArgentinaFil: Gómez Chávez, José Leonardo. Universidad Nacional del Nordeste. Facultad de Ciencias Exactas y Naturales y Agrimensura. Departamento de Química. Laboratorio de Estructura Molecular y Propiedades; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Nordeste. Instituto de Química Básica y Aplicada del Nordeste Argentino. Universidad Nacional del Nordeste. Facultad de Ciencias Exactas Naturales y Agrimensura. Instituto de Química Básica y Aplicada del Nordeste Argentino; ArgentinaFil: Angelina, Emilio Luis. Universidad Nacional del Nordeste. Facultad de Ciencias Exactas y Naturales y Agrimensura. Departamento de Química. Laboratorio de Estructura Molecular y Propiedades; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Nordeste. Instituto de Química Básica y Aplicada del Nordeste Argentino. Universidad Nacional del Nordeste. Facultad de Ciencias Exactas Naturales y Agrimensura. Instituto de Química Básica y Aplicada del Nordeste Argentino; ArgentinaFil: Peruchena, Nelida Maria. Universidad Nacional del Nordeste. Facultad de Ciencias Exactas y Naturales y Agrimensura. Departamento de Química. Laboratorio de Estructura Molecular y Propiedades; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Nordeste. Instituto de Química Básica y Aplicada del Nordeste Argentino. Universidad Nacional del Nordeste. Facultad de Ciencias Exactas Naturales y Agrimensura. Instituto de Química Básica y Aplicada del Nordeste Argentino; ArgentinaXI Congreso Argentino de Bioinformática y Biología ComputacionalBuenos AiresArgentinaAsociacion Argentina de Bioinformática y Biología ComputacionalAsociación Argentina de Bioinformática y Biología Computacional2021info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/conferenceObjectCongresoBookhttp://purl.org/coar/resource_type/c_5794info:ar-repo/semantics/documentoDeConferenciaapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/170855Drug repurposing to find inhibitors of SARS-CoV-2 main protease; XI Congreso Argentino de Bioinformática y Biología Computacional; Buenos Aires; Argentina; 2021; 1-2CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/http://2021.a2b2c.org.ar/Book.pdfInternacionalinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:34:07Zoai:ri.conicet.gov.ar:11336/170855instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:34:07.858CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Drug repurposing to find inhibitors of SARS-CoV-2 main protease |
title |
Drug repurposing to find inhibitors of SARS-CoV-2 main protease |
spellingShingle |
Drug repurposing to find inhibitors of SARS-CoV-2 main protease Conti, German Andres Cribado Virtual COVID-19 |
title_short |
Drug repurposing to find inhibitors of SARS-CoV-2 main protease |
title_full |
Drug repurposing to find inhibitors of SARS-CoV-2 main protease |
title_fullStr |
Drug repurposing to find inhibitors of SARS-CoV-2 main protease |
title_full_unstemmed |
Drug repurposing to find inhibitors of SARS-CoV-2 main protease |
title_sort |
Drug repurposing to find inhibitors of SARS-CoV-2 main protease |
dc.creator.none.fl_str_mv |
Conti, German Andres Gómez Chávez, José Leonardo Angelina, Emilio Luis Peruchena, Nelida Maria |
author |
Conti, German Andres |
author_facet |
Conti, German Andres Gómez Chávez, José Leonardo Angelina, Emilio Luis Peruchena, Nelida Maria |
author_role |
author |
author2 |
Gómez Chávez, José Leonardo Angelina, Emilio Luis Peruchena, Nelida Maria |
author2_role |
author author author |
dc.subject.none.fl_str_mv |
Cribado Virtual COVID-19 |
topic |
Cribado Virtual COVID-19 |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/1.2 https://purl.org/becyt/ford/1 |
dc.description.none.fl_txt_mv |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the strain of coronavirus that causes coronavirus disease 2019 (COVID-19), the respiratory illness responsible for the COVID-19 pandemic. As of October 2021, with about 6 billion doses of COVID-19 vaccines administered globally, the world is slowly returning back to normality. However, there is still a need for novel therapeutics for people that contracted the disease either because they were not vaccinated or because the vaccine was not effective for them. Drug repurposing is a strategy for identifying new uses for approved drugs that has the advantage, over conventional approaches that attempt to develop a drug from scratch, that the time frame of the overall process can be significantly reduced because of the few number of clinical trials required. In this work, a structure-based virtual screening of FDA-approved drugs was performed for repositioning as potential inhibitors of the main protease Mpro of SARS-CoV-2. 12 drugs were prioritized from the Virtual Screening campaigns as potential inhibitors of the Mpro enzyme. Some of the selected compounds turned out to be antiviral drugs already being tested in COVID-19 clinical trials or used to alleviate symptoms of the disease. Curiously, the most promising candidate is the naturally occurring broad spectrum antibiotic Oxytetracycline (OTC). This drug has largely outperformed the remaining selected candidates along all filtering steps of the virtual screening workflow. The closely related tetracycline-derived drug Doxycycline (DOX) recently has proven to reduce the viral load in Vero cells infected with SARS-CoV-2. Since OTC but not DOX surpassed the more stringent filters in the late stages of our virtual screening pipeline, we suspect that OTC will show even higher antiviral activity than DOX in viral replication experiments.Considering our computational findings together with the proven antiviral properties of DOX, we believe it is worth testing OTC in prospective viral replication studies. We encourage the scientific community working on COVID-19 projects to include this repurposing candidate on their experimental screening pipelines. Fil: Conti, German Andres. Universidad Nacional del Nordeste. Facultad de Ciencias Exactas y Naturales y Agrimensura. Departamento de Química. Laboratorio de Estructura Molecular y Propiedades; Argentina Fil: Gómez Chávez, José Leonardo. Universidad Nacional del Nordeste. Facultad de Ciencias Exactas y Naturales y Agrimensura. Departamento de Química. Laboratorio de Estructura Molecular y Propiedades; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Nordeste. Instituto de Química Básica y Aplicada del Nordeste Argentino. Universidad Nacional del Nordeste. Facultad de Ciencias Exactas Naturales y Agrimensura. Instituto de Química Básica y Aplicada del Nordeste Argentino; Argentina Fil: Angelina, Emilio Luis. Universidad Nacional del Nordeste. Facultad de Ciencias Exactas y Naturales y Agrimensura. Departamento de Química. Laboratorio de Estructura Molecular y Propiedades; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Nordeste. Instituto de Química Básica y Aplicada del Nordeste Argentino. Universidad Nacional del Nordeste. Facultad de Ciencias Exactas Naturales y Agrimensura. Instituto de Química Básica y Aplicada del Nordeste Argentino; Argentina Fil: Peruchena, Nelida Maria. Universidad Nacional del Nordeste. Facultad de Ciencias Exactas y Naturales y Agrimensura. Departamento de Química. Laboratorio de Estructura Molecular y Propiedades; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Nordeste. Instituto de Química Básica y Aplicada del Nordeste Argentino. Universidad Nacional del Nordeste. Facultad de Ciencias Exactas Naturales y Agrimensura. Instituto de Química Básica y Aplicada del Nordeste Argentino; Argentina XI Congreso Argentino de Bioinformática y Biología Computacional Buenos Aires Argentina Asociacion Argentina de Bioinformática y Biología Computacional |
description |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the strain of coronavirus that causes coronavirus disease 2019 (COVID-19), the respiratory illness responsible for the COVID-19 pandemic. As of October 2021, with about 6 billion doses of COVID-19 vaccines administered globally, the world is slowly returning back to normality. However, there is still a need for novel therapeutics for people that contracted the disease either because they were not vaccinated or because the vaccine was not effective for them. Drug repurposing is a strategy for identifying new uses for approved drugs that has the advantage, over conventional approaches that attempt to develop a drug from scratch, that the time frame of the overall process can be significantly reduced because of the few number of clinical trials required. In this work, a structure-based virtual screening of FDA-approved drugs was performed for repositioning as potential inhibitors of the main protease Mpro of SARS-CoV-2. 12 drugs were prioritized from the Virtual Screening campaigns as potential inhibitors of the Mpro enzyme. Some of the selected compounds turned out to be antiviral drugs already being tested in COVID-19 clinical trials or used to alleviate symptoms of the disease. Curiously, the most promising candidate is the naturally occurring broad spectrum antibiotic Oxytetracycline (OTC). This drug has largely outperformed the remaining selected candidates along all filtering steps of the virtual screening workflow. The closely related tetracycline-derived drug Doxycycline (DOX) recently has proven to reduce the viral load in Vero cells infected with SARS-CoV-2. Since OTC but not DOX surpassed the more stringent filters in the late stages of our virtual screening pipeline, we suspect that OTC will show even higher antiviral activity than DOX in viral replication experiments.Considering our computational findings together with the proven antiviral properties of DOX, we believe it is worth testing OTC in prospective viral replication studies. We encourage the scientific community working on COVID-19 projects to include this repurposing candidate on their experimental screening pipelines. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/conferenceObject Congreso Book http://purl.org/coar/resource_type/c_5794 info:ar-repo/semantics/documentoDeConferencia |
status_str |
publishedVersion |
format |
conferenceObject |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/170855 Drug repurposing to find inhibitors of SARS-CoV-2 main protease; XI Congreso Argentino de Bioinformática y Biología Computacional; Buenos Aires; Argentina; 2021; 1-2 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/170855 |
identifier_str_mv |
Drug repurposing to find inhibitors of SARS-CoV-2 main protease; XI Congreso Argentino de Bioinformática y Biología Computacional; Buenos Aires; Argentina; 2021; 1-2 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/http://2021.a2b2c.org.ar/Book.pdf |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf application/pdf |
dc.coverage.none.fl_str_mv |
Internacional |
dc.publisher.none.fl_str_mv |
Asociación Argentina de Bioinformática y Biología Computacional |
publisher.none.fl_str_mv |
Asociación Argentina de Bioinformática y Biología Computacional |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844613054866653184 |
score |
13.070432 |